NCT06120972 2025-02-12
Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
University of Pittsburgh
Phase 2 Withdrawn
Clinical Trials
56 trialsNCT05145569 2025-01-01
Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer
University of Pittsburgh
Phase 2 Withdrawn
NCT06099418 2024-09-20
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
Nykode Therapeutics ASA
Phase 2 Withdrawn
NCT06046274 2024-04-30
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
Genmab
Phase 2 Withdrawn
NCT05033132 2024-03-28
A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer
Agenus Inc.
Phase 2 Withdrawn
NCT04102436 2024-03-12
Non-Viral TCR Gene Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT05295589 2023-09-26
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT05201001 2023-09-11
APX005M
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 2 Withdrawn
NCT05736952 2023-05-11
Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Withdrawn
NCT05504642 2023-04-18
CERAD-IMMUNE
Universitätsklinikum Köln
Phase 2 Withdrawn
NCT05405192 2023-02-28
Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia
University of Miami
Phase 2 Withdrawn
NCT05419817 2023-02-27
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
University of Pittsburgh
Phase 2 Withdrawn
NCT04294836 2022-12-07
Curcumin in Advanced Cervical Cancer
Instituto Nacional de Cancerologia, Columbia
Phase 2 Withdrawn
NCT03834571 2022-06-21
Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women
AIDS Malignancy Consortium
Phase 2 Withdrawn
NCT01244438 2021-12-13
Study of FP-1039 in Subjects With Endometrial Cancers
Five Prime Therapeutics, Inc.
Phase 2 Withdrawn
NCT03933761 2021-08-10
PRECISE
Australia New Zealand Gynaecological Oncology Group
Phase 2 Withdrawn
NCT02127151 2021-08-06
PANDA
University College, London
Phase 2 Withdrawn
NCT04239014 2021-03-10
DUETTE
AstraZeneca
Phase 2 Withdrawn
NCT01925378 2020-11-12
A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia
The University of Texas Health Science Center, Houston
Phase 2 Withdrawn
NCT04197219 2020-11-05
Pembrolizumab With Axitinib in Recurrent Endometrial Cancer
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT04561817 2020-10-06
To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Withdrawn
NCT01019278 2020-04-03
Proton Beam Radiation Therapy and Cisplatin in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer and Positive Lymph Nodes
Abramson Cancer Center at Penn Medicine
Phase 2 Withdrawn
NCT02487849 2020-03-04
HIPEC
Krankenhaus Barmherzige Schwestern Linz
Phase 2 Withdrawn
NCT01766622 2019-12-04
18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT03795272 2019-11-01
MaRuC
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 2 Withdrawn
NCT03836157 2019-06-27
Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
University of Oklahoma
Phase 2 Withdrawn
NCT02948101 2019-03-12
PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00257829 2018-12-03
Improving Tumor Oxygenation in Cervical Cancer
University of California, Irvine
Phase 2 Withdrawn
NCT03161041 2018-11-14
Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study
Hospices Civils de Lyon
Phase 2 Withdrawn
NCT03220009 2018-10-03
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00003821 2018-09-18
Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer
Sanofi
Phase 2 Withdrawn
NCT02836028 2018-09-18
A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer
Pfizer
Phase 2 Withdrawn
NCT00950261 2018-08-13
Efficacy Study for Postoperative Chemoradiation Using Triweekly Cisplatin in Cervical Cancer Patients
Korea Cancer Center Hospital
Phase 2 Withdrawn
NCT03143491 2017-10-18
Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN)
DFB Soria, LLC
Phase 2 Withdrawn
NCT03032614 2017-10-10
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
The University of Texas Health Science Center at San Antonio
Phase 2 Withdrawn
NCT00600210 2017-08-23
Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer
Leo W. Jenkins Cancer Center
Phase 2 Withdrawn
NCT00408967 2017-08-18
Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.
EMD Serono
Phase 2 Withdrawn
NCT00003865 2017-07-13
Toremifene in Treating Patients With Ovarian Cancer
George Washington University
Phase 2 Withdrawn
NCT01095523 2017-07-02
Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT03005015 2016-12-29
Lenvatinib in Second Line Endometrial Carcinoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT02042495 2016-08-30
Endometrial Cancer Biomarker Changes Following Exposure to Metformin
Jewish General Hospital
Phase 2 Withdrawn
NCT02501278 2016-05-13
A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT00634894 2016-04-20
Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00365443 2015-06-19
Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)
Merck Sharp & Dohme LLC
Phase 2 Withdrawn
NCT02095847 2015-04-08
High-Resolution Microendoscopy to Guide Hysteroscopic Tumor Resection
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02017678 2014-09-17
Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin
Mount Sinai Hospital, Canada
Phase 2 Withdrawn
NCT01943058 2014-09-10
Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer
University of Southern California
Phase 2 Withdrawn
NCT01550380 2014-07-29
BKM120
University of Utah
Phase 2 Withdrawn
NCT00003094 2014-05-20
Carotenoid Rich Diet in Treating Cervical Dysplasia
University of California, San Diego
Phase 2 Withdrawn
NCT00072540 2013-11-08
S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix
SWOG Cancer Research Network
Phase 2 Withdrawn